Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.34 |
| ▸ | TUBB | P07437 | 3/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2889988 | 1.00 | NFE2L2 (0.37) | NFE2L2KDM4EALDH1A1LMNAPOLB | |
| SCHEMBL2889796 | 0.78 | GRM5 (0.46) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL2889795 | 0.78 | GRM5 (0.46) | KDM4EALDH1A1LMNAPOLBGLA | |
| SCHEMBL5751791 | 0.74 | RXRA (0.36) | NFE2L2KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL2895689 | 0.69 | NOTUM (0.42) | KDM4EPTGS2KMT2A | |
| SCHEMBL2897290 | 0.68 | GRM5 (0.46) | ALDH1A1LMNAHPGDCASP3SENP8 | |
| SCHEMBL2897293 | 0.68 | GRM5 (0.46) | ALDH1A1LMNAHPGDCASP3SENP8 | |
| SCHEMBL2897163 | 0.68 | APP (0.39) | KDM4EALDH1A1LMNAPOLBHPGD | |
| SCHEMBL2889889 | 0.66 | KCNH2 (0.33) | GRM5 | |
| SCHEMBL14947044 | 0.61 | AHR (0.61) | NFE2L2KDM4EALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716125-B1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2013-06-19 | — | — | EP | disclosed |
| US-7691892-B2 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| EP-1716125-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | AstraZeneca AB (SE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB | 2006-01-05 | — | — | US | disclosed |
| WO-2005080356-A1 | TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004021-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | NFE2L2 4467/4885KDM4E 2623/4885ALDH1A1 2803/4885 |
| US-20070197549-A1 | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists | GRM1, GRM3, GRM4 | NFE2L2 4533/4885KDM4E 2698/4885ALDH1A1 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.